| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Lymphoma Research Unit, Tenovus Laboratory, General Hospital, Southampton, United Kingdom;
Wellcome Trust Immunology Center, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom;
Institute for Animal Health, Pirbright, United Kingdom; and
§
National Institute for Medical Research, London, United Kingdom
Despite the recent success of mAb in the treatment of certain malignancies, there is still considerable uncertainty about the mechanism of action of anti-cancer Abs. Here, a panel of rat anti-mouse B cell mAb, including Ab directed at surface IgM Id, CD19, CD22, CD40, CD74, and MHC class II, has been investigated in the treatment of two syngeneic mouse B cell lymphomas, BCL1 and A31. Only three mAb were therapeutically active in vivo, anti-Id, anti-CD19, and anti-CD40. mAb to the other Ags showed little or no therapeutic activity in either model despite giving good levels of surface binding and activity in Ag-dependent cellular cytotoxicity and complement assays, and in some cases inhibiting cell growth in vitro. We conclude that the activity of mAb in vitro does not predict therapeutic performance in vivo. Furthermore, in vivo tracking experiments using fluorescently tagged cells showed that anti-Id and anti-CD40 mAb probably operate via different mechanisms: the anti-Id mAb cause growth arrest that is almost immediate and does not eliminate cells over a period of 5 or 6 days, and the anti-CD40 mAb have a delayed effect that allows tumor to grow normally for 3 days, but then abruptly eradicates lymphoma cells. This work supports the belief that mAb specificity is critical to therapeutic success in lymphoma and that, in addition to any effector-recruiting activity they may possess, in vivo mAb operate via mechanisms that involve cross-linking and signaling of key cellular receptors.
This article has been cited by other articles:
|
|
 |
|
  C. A. Walshe, S. A. Beers, R. R. French, C. H. T. Chan, P. W. Johnson, G. K. Packham, M. J. Glennie, and M. S. Cragg Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling J. Biol. Chem., June 20, 2008; 283(25): 16971 - 16984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Y. Taraban, S. Martin, K. E. Attfield, M. J. Glennie, T. Elliott, D. Elewaut, S. Van Calenbergh, B. Linclau, and A. Al-Shamkhani Invariant NKT Cells Promote CD8+ Cytotoxic T Cell Responses by Inducing CD70 Expression on Dendritic Cells J. Immunol., April 1, 2008; 180(7): 4615 - 4620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Peipp, T. Schneider-Merck, M. Dechant, T. Beyer, J. J. Lammerts van Bueren, W. K. Bleeker, P. W. H. I. Parren, J. G. J. van de Winkel, and T. Valerius Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations J. Immunol., March 15, 2008; 180(6): 4338 - 4345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Du, J. Honeychurch, M. Glennie, P. Johnson, and T. Illidge Microscopic Intratumoral Dosimetry of Radiolabeled Antibodies Is a Critical Determinant of Successful Radioimmunotherapy in B-Cell Lymphoma Cancer Res., February 1, 2007; 67(3): 1335 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Teeling, W. J. M. Mackus, L. J. J. M. Wiegman, J. H. N. van den Brakel, S. A. Beers, R. R. French, T. van Meerten, S. Ebeling, T. Vink, J. W. Slootstra, et al. The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20 J. Immunol., July 1, 2006; 177(1): 362 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Shorts, J. M. Weiss, J.-K. Lee, L. A. Welniak, J. Subleski, T. Back, W. J. Murphy, and R. H. Wiltrout Stimulation through CD40 on Mouse and Human Renal Cell Carcinomas Triggers Cytokine Production, Leukocyte Recruitment, and Antitumor Responses that Can Be Independent of Host CD40 Expression. J. Immunol., June 1, 2006; 176(11): 6543 - 6552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Honeychurch, M. J. Glennie, and T. M. Illidge Cyclophosphamide Inhibition of Anti-CD40 Monoclonal Antibody-Based Therapy of B Cell Lymphoma Is Dependent on CD11b+ Cells Cancer Res., August 15, 2005; 65(16): 7493 - 7501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Cragg, M. B. Bayne, A. L. Tutt, R. R. French, S. Beers, M. J. Glennie, and T. M. Illidge A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells Blood, October 15, 2004; 104(8): 2540 - 2542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Teeling, R. R. French, M. S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. H. I. Parren, C. E. Hack, M. Dechant, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas Blood, September 15, 2004; 104(6): 1793 - 1800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Du, J. Honeychurch, M. S. Cragg, M. Bayne, M. J. Glennie, P. W. M. Johnson, and T. M. Illidge Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy Blood, February 15, 2004; 103(4): 1485 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. T. C. Chan, D. Hughes, R. R. French, A. L. Tutt, C. A. Walshe, J. L. Teeling, M. J. Glennie, and M. S. Cragg CD20-induced Lymphoma Cell Death Is Independent of Both Caspases and Its Redistribution into Triton X-100 Insoluble Membrane Rafts Cancer Res., September 1, 2003; 63(17): 5480 - 5489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Honeychurch, M. J. Glennie, P. W. M. Johnson, and T. M. Illidge Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma Blood, August 15, 2003; 102(4): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Goodyear and G. J. Silverman Death by a B Cell Superantigen: In Vivo VH-targeted Apoptotic Supraclonal B Cell Deletion by a Staphylococcal Toxin J. Exp. Med., May 5, 2003; 197(9): 1125 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. C. Sheu, T. Cheng, H. Y. Chen, C. Lim, and T.-W. Chang Comparative Effects of Human Ig{alpha} and Ig{beta} in Inducing Autoreactive Antibodies Against B Cells in Mice J. Immunol., February 1, 2003; 170(3): 1158 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Cragg, S. M. Morgan, H. T. C. Chan, B. P. Morgan, A. V. Filatov, P. W. M. Johnson, R. R. French, and M. J. Glennie Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts Blood, February 1, 2003; 101(3): 1045 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tiroch, B. Stockmeyer, C. Frank, and T. Valerius Intracellular Domains of Target Antigens Influence Their Capacity to Trigger Antibody-Dependent Cell-Mediated Cytotoxicity J. Immunol., April 1, 2002; 168(7): 3275 - 3282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Tutt, L. O'Brien, A. Hussain, G. R. Crowther, R. R. French, and M. J. Glennie T Cell Immunity to Lymphoma Following Treatment with Anti-CD40 Monoclonal Antibody J. Immunol., March 15, 2002; 168(6): 2720 - 2728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Q. Feng, K. Mozdzanowska, and W. Gerhard Complement Component C1q Enhances the Biological Activity of Influenza Virus Hemagglutinin-Specific Antibodies Depending on Their Fine Antigen Specificity and Heavy-Chain Isotype J. Virol., February 1, 2002; 76(3): 1369 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-A. Ghetie, H. Bright, and E. S. Vitetta Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin Blood, March 1, 2001; 97(5): 1392 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Jahrsdörfer, G. Hartmann, E. Racila, W. Jackson, L. Mühlenhoff, G. Meinhardt, S. Endres, B. K. Link, A. M. Krieg, and G. J. Weiner CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens J. Leukoc. Biol., January 1, 2001; 69(1): 81 - 88. [Abstract] [Full Text]
|
|
|
|
|
|
S. Mathas, A. Rickers, K. Bommert, B. Dörken, and M. Y. Mapara Anti-CD20- and B-cell Receptor-mediated Apoptosis: Evidence for Shared Intracellular Signaling Pathways Cancer Res., December 1, 2000; 60(24): 7170 - 7176. [Abstract] [Full Text]
|
|
|
|
|
|
J. Honeychurch, A. L. Tutt, T. Valerius, I. A. F. M. Heijnen, J. G. J. Van de Winkel, and M. J. Glennie Therapeutic efficacy of Fcgamma RI/CD64-directed bispecific antibodies in B-cell lymphoma Blood, November 15, 2000; 96(10): 3544 - 3552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Francisco, K. L. Donaldson, D. Chace, C. B. Siegall, and A. F. Wahl Agonistic Properties and in Vivo Antitumor Activity of the Anti-CD40 Antibody SGN-14 Cancer Res., June 1, 2000; 60(12): 3225 - 3231. [Abstract] [Full Text]
|
|
|
|
|
|
T. M. Illidge, M. S. Cragg, H. M. McBride, R. R. French, and M. J. Glennie The Importance of Antibody-Specificity in Determining Successful Radioimmunotherapy of B-Cell Lymphoma Blood, July 1, 1999; 94(1): 233 - 243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Syrengelas and R. Levy DNA Vaccination Against the Idiotype of a Murine B Cell Lymphoma: Mechanism of Tumor Protection J. Immunol., April 15, 1999; 162(8): 4790 - 4795. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
